Despite advances, the roles of genetics and microenvironment in CLL are not fully understood, and curative treatments may ...

Multiple sclerosis (MS) includes both peripheral and central nervous system (CNS) inflammation, and an anti-inflammatory ...

A UK biotech firm spent years gathering genetic data that has uncovered 1 million previously unknown microbial species and ...

New data support tailoring regional nodal irradiation in patients treated with neoadjuvant chemotherapy on the basis of their ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented today results from the Phase III SUNMO ...

The initial report of monotherapy with the BCL-2 inhibitor venetoclax showed it had durable clinical activity and favorable ...

Bevacizumab (Avastin) combined with erlotinib (Tarceva) showed activity in patients with hereditary leiomyomatosis and renal ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today its decision to proceed with Phase III ...

Those adjustments just keep coming. As SFGATE reported, Genentech announced 436 layoffs in April 2024, and 93 more layoffs ...

Other appointments to BIO's board for the 2025 through 2026 term include: Arcutis Bio's Frank Watanabe, named vice-chair; ...

Genentech is letting go of 143 employees who are based out of the company's headquarters in South San Francisco. | Genentech ...

After enduring multiple rounds of layoffs last year, Genentech’s employees are facing more uncertainty as the Roche unit lets ...